Skip to main content

Table 2 Groups of animals tested to evaluate the safety, efficacy, and immunogenicity of DEV-H5(UL55)

From: Construction of a recombinant duck enteritis virus (DEV) expressing hemagglutinin of H5N1 avian influenza virus based on an infectious clone of DEV vaccine strain and evaluation of its efficacy in ducks and chickens

Group

Vaccine or PBS

Dose

Animal/age

A-DP(5D)

DEV-H5(UL55)

1 × 106 TCID50, 0.2 mL

Ducks/5wa

B-DP(5D)

DEV vaccine

1 × 106 TCID50, 0.2 mL

Ducks/5w

C-DP(5D)

PBS

0.2 mL

Ducks/5w

D-DP(5D)

PBS

0.2 mL

Ducks/5w

A-AI(2D)

DEV-H5(UL55)

1 × 107 TCID50, 0.2 mL

Ducks/2wb

B-AI(2D)

DEV-H5(UL55)

1 × 106 TCID50, 0.2 mL

Ducks/2w

C-AI(2D)

DEV-H5(UL55)

1 × 105 TCID50, 0.2 mL

Ducks/2w

D-AI(2D)

Inactivated AI(H5N1) Re-6 vaccine

0.5 mL and 1 mL at 2w and 5w respectively

Ducks/2w

E-AI(2D)

PBS

0.2 mL

Ducks/2w

A-AI(1C)

DEV-H5(UL55)

1 × 107 TCID50, 0.2 mL

SPF chickens/1wc

B-AI(1C)

DEV-H5(UL55)

1 × 106 TCID50, 0.2 mL

SPF chickens/1w

C-AI(1C)

DEV-H5(UL55)

1 × 105 TCID50, 0.2 mL

SPF chickens/1w

D-AI(1C)

Inactivated AI(H5N1) Re-6 vaccine

0.3 mL

SPF chickens/1w

E-AI(1C)

PBS

0.2 mL

SPF chickens/1w

A-AI(3C)

DEV-H5(UL55)

1 × 107 TCID50, 0.2 mL

Layers/3wd

B-AI(3C)

DEV-H5(UL55)

1 × 106 TCID50, 0.2 mL

Layers/3w

C-AI(3C)

DEV-H5(UL55)

1 × 105 TCID50, 0.2 mL

Layers/3w

D-AI(3C)

Inactivated AI(H5N1) Re-6 vaccine

0.3 mL

Layers/3w

E-AI(3C)

PBS

0.2 mL

Layers/3w

  1. aA total of 40 5-week-old commercial ducks were randomly divided into four groups of A-DP(5D), B-DP(5D), C-DP(5D), and D-DP(5D) to test the safety and protection efficiency of DEV-H5(UL55) against virulent DEV challenge
  2. bA total of 50 2-week-old commercial ducks were randomly divided into five groups of A-AI(2D), B-AI(2D), C-AI(2D), D-AI(2D), and E-AI(2D) to test of safety and potency of DEV-H5(UL55) in stimulation of HI antibodies against AI(H5N1), compared with inactivated AI(H5N1) Re-6 vaccine
  3. cA total of 50 1-week-old SPF chickens were randomly divided into five groups of A-AI(1C), B-AI(1C), C-AI(1C), D-AI(1C), and E-AI(1C) to test the safety and potency of DEV-H5(UL55) in the stimulation of HI antibodies against AI(H5N1)
  4. dA total of 50 3-week-old commercial layer chickens were randomly divided into five groups of A-AI(3C), B-AI(3C), C-AI(3C), D-AI(3C), and E-AI(3C) to test the safety and potency of DEV-H5(UL55) in the stimulation of HI antibodies against AI(H5N1)